Drug intelligence / Profile preview

colesevelam + pioglitazone

Development stage
Unknown
Lead developer
Daiichi Sankyo
Modality
Small Molecules
Administration
Oral
01

Overview

**Colesevelam + pioglitazone** is a combination regimen used in the management of **type 2 diabetes mellitus**. **Colesevelam** is a bile acid sequestrant that lowers LDL cholesterol and improves glycemic control by binding bile acids in the intestine, thereby reducing their reabsorption. **Pioglitazone** is a thiazolidinedione that enhances insulin sensitivity through activation of peroxisome proliferator-activated receptor gamma (PPARγ), which regulates glucose and lipid metabolism. This combination improves glycemic parameters (HbA1c, fasting plasma glucose) and lipid profiles (reducing LDL cholesterol, total cholesterol, apolipoprotein B, non-HDL cholesterol and raising HDL cholesterol), and is generally well tolerated with mild or moderate adverse events[1][2]. The main indication is for **adults with type 2 diabetes** who have inadequate glycemic control on pioglitazone-based therapy.

Other names
colesevelam + pioglitazone
02

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on colesevelam + pioglitazone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on colesevelam + pioglitazone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call